Preface

The book *Central Nervous System Tumors* represents the contribution of many experts in the field, each with his own specialty and interests. The management of patients with tumors of the central nervous system (CNS) is complex and involves the expertise of many disciplines including neuro-oncology, neuroradiology, neurosurgery, radiation oncology, neuropathology, and more. Many of our patients are quite debilitated and require the aid of physical and occupational therapy, spiritual counseling, pain management, and palliative care. Our field has changed greatly over the past several years as we gain a better understanding of the mechanisms of tumorigenesis and the genes involved. Many of them can be targeted with new pharmaceuticals, and immunotherapy is a very active area of research. We rely heavily on new breakthroughs from basic science research labs around the world.

I am grateful for the wonderful and exciting contributions from the many authors that have helped with the publication of this book, and I remain hopeful for the future of the field with the many new advances that are sure to come in the years ahead. I also would like to thank our *IntechOpen* colleagues for their help and support in bringing the most up-to-date findings to its readers.

> **Dr. Scott George Turner** Associate Professor of Neurology, Department of Neuro-Oncology, University of California, Irvine, Orange, CA

Section 1 Introduction

#### **Chapter 1**

## Introductory Chapter: The Current State of the Treatment of CNS Malignancies

*Scott George Turner*

#### **1. Introduction**

The management of patients with malignancies of the central nervous system (CNS) has presented a challenge for many years. For benign tumors such as pituitary adenomas or low-grade meningiomas, surgery is often adequate to ensure a good outcome, whereas for high-grade gliomas, maximal surgery followed by radiation and chemotherapy is the standard of care. Newer modalities such as immunotherapy and tumor-treating fields have shown benefit, and have been added to the armamentarium that neuro-oncologists employ to care for patients with challenging high-grade tumors.

#### **2. WHO classification**

In 2016, the World Health Organization (WHO) revised its classification scheme for tumors of the central nervous system. The 2000 [1] and 2007 [2] classification schemes relied on histologic findings, including immunohistochemistry, to determine tumor type based on similarities to the cell of origin, as well as tumor grade. The 2016 [3] changes combined the histologic findings with genetic information in order to better characterize these tumors and to establish data on prognosis. An updated classification scheme is coming this year [4] and builds on the 2016 version, incorporating updated molecular and genetic biomarkers.

#### **3. Pediatric CNS tumors**

CNS tumors are the most common solid tumors in children. The ones most commonly found in the posterior fossa are medulloblastoma, juvenile pilocytic astrocytoma, ependymoma, diffuse pontine glioma, and atypical teratoid-rhabdoid tumor [5]. Medulloblastomas [6] are characterized by molecular features and histopathology, and there are four subtypes: WNT-activated, SHH-activated, and Group 3 and Group 4 non-WNT/non-SHH. Each subtype has its own molecular and histologic characteristics, and all are considered WHO Grade 4. Ependymomas [7] occur in both adults and children and can occur in the brain and spinal cord. The majority occur in the posterior fossa and can be WHO Grade 2 or 3. A supratentorial RELAfusion-positive variant was first described in 2016. Astrocytomas, oligodendrogliomas, craniopharyngiomas, gangliogliomas, primitive neuroectodermal tumors, and meningiomas are most often found supratentorially. Often these are low-grade, slow-growing tumors that can be treated with surgery alone.

#### **4. Adult CNS tumors**

Meningiomas [8] arise from the meninges and are most often benign, Grade I tumors, though there are rare higher-grade meningiomas that can invade into the brain tissue. As mentioned above, ependymomas can occur in both children and adults. A myxopapillary variant is commonly found at the filum/cauda equina and is more common in adults. The new 2021 WHO classification has changed this subtype from a Grade 1 tumor to Grade 2 due to its more aggressive clinical course. The two glands within the brain also can develop tumors: Pituitary adenomas [9] arise from the pituitary gland within the sella turcica and can cause endocrinopathies and visual field loss. Tumors of the pineal gland [10] can lead to symptoms from hydrocephalus, among others. However, the most common primary CNS tumor is also the most aggressive, glioblastoma multiforme, which are classified as IDH mutant or wildtype with very different survival outcomes. Maximal surgical resection correlates with better survival [11], and surgical advances have led to improved outcomes. Following surgery, post-operative radiation and chemotherapy are the standard of care. Only temozolomide chemotherapy [12] and Optune tumor-treating fields [13] have been shown to improve overall survival in these patients, though new therapies are being investigated.

Neuro-oncology remains a very exciting field with new therapies being developed based on our better understanding of the genetics and molecular characteristics of these tumors. Targeted therapies [14] and immunotherapy [15], including vaccines, are being developed. This is truly a very exciting time for the field, and I am sure that, as our understanding of the most aggressive types of primary brain tumors grows, we will make even greater strides toward successfully treating these deadly malignancies.

#### **Author details**

Scott George Turner Department of Neuro-Oncology, University of California, Irvine, Orange, CA, USA

\*Address all correspondence to: sgturne1@hs.uci.edu

© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/ by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

*Introductory Chapter: The Current State of the Treatment of CNS Malignancies DOI: http://dx.doi.org/10.5772/intechopen.101599*

#### **References**

[1] Kleihues P et al. The WHO classification of tumours of the central nervous system. Journal of Neuropathology & Experimental Neurology. 2002;**3**:15-225

[2] Louis DN et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathologica. 2007;**114**(2):97-109

[3] Louis DN et al. The 2016 WHO classification of tumours of the central nervous system: A summary. Acta Neuropathologica. 2016;**131**(6):803-820

[4] Louis DN et al. The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncology. 2021;**23**(8):1231-1251

[5] Udaka Y, Packer R. Pediatric brain tumors. Neurologic Clinics. 2018;**36**(3): 533-556

[6] Quinlan A, Rizzolo D. Understanding medulloblastoma. JAAPA. 2017;**30**(10): 30-36

[7] Gerstner ER, Pajtler KW. Ependymoma. Seminars in Neurology. 2018;**38**(1):104-111

[8] Apra C et al. Current treatment options for meningioma. Expert Review of Neurotherapeutics. 2018;**18**(3): 241-249

[9] Penar P et al. Pituitary tumor diagnosis and treatment. Current Neurology and Neuroscience Reports. 2002;**2**(3):236-245

[10] Mottolese C et al. History of the pineal region tumor. Neurochirurgie. 2015;**61**(2-3):61-64

[11] Lacroix M et al. Extent of surgery correlates with survival and surgical advances have led to improved survival. We include a discussion of awake

craniotomies and new neuro-navigation and brain mapping techniques for surgical planning. Journal of Neurosurgery. 2001;**92**(2):190-198

[12] Stupp R et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. NEJM. 2005;**352**:987-996

[13] Stupp R et al. Effect of tumortreating fields plus maintenance Temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma. JAMA. 2017;**318**(23):2306-2316

[14] Mercer R et al. Targeted therapies for malignant glioma. BioDrugs. 2009;**23**(1):25-35

[15] Kamran N et al. Current state and future prospects of immunotherapy for glioma. Immunotherapy. 2018;**10**(4): 317-339

Section 2
